氟伐他汀钠缓释片调脂治疗的临床观察

摘要

Objective: To observe the clinical efficacy and safety of Fluvastatin Sodium Extended Release Tablets on lipid-modulating. Methods: 60 cases of patients with dyslipidemia were randomly divided into Fluvastatin group and Atorvastatin group by the method of random number table, with 30 patients in each group. The patients in Fluvastatin group were treated with Fluvastatin Sodium Extended Release Tablets (80 mg/d) and the patients in Atorvastatin group were treated with Atorvastatin Calcium Tablets (20 mg/d). Before treatment and the 1, 2, 4, 8 and 12 weeks after treatment, the serum total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterin (HDL-C), triglycercide (TG), glutamic pyruvic transaminase (ALT), glutamic oxaloacetic transaminase (AST) and creatine phosphokinase (CK) were measured. Results: After 12 weeks treatment, TC, LDL-C and TG of Fluvastatin group reduced from (6.07±1.23), (3.33+0.61), (1.71±0.34) mmol/L to (3.79±0.41), (2.46±0.23), (1.19+0.10) mmol/L respectively. TC, LDL-C and TG of Atorvastatin group reduced from (6.03 ±1.19), (3.39 ±0.65), (1.75 ±0.37) mmol/L to (3.87 ±0.45), (2.55 ±0.27), (1.23+0.13) mmol/L respectively, TC, LDL-C and TG of both groups were reduced observably (P<0.01). The incidence rate of adverse reactions of Fluvastatin group was lower than that of Atorvastatin group and the difference was significant (P< 0.05). Conclusion: Both Fluvastatin Sodium Extended Release Tablets and Atorvastatin Calcium Tablets are effective in treatment of dyslipidemia. Fluvastatin Sodium Extended Release Tablets is superior to Atorvastatin Calcium Tablets in safety. Treatment with Fluvastatin Sodium Extended Release Tablets offers an effective, safe and convenient approach to modulating lipid.%目的:观察氟伐他汀钠缓释片调脂治疗的临床疗效和安全性.方法:采用随机数字表法将60例血脂异常患者平均分成两组.氟伐他汀组给予氟伐他汀钠缓释片 80 mg/d;阿托伐他汀组给予阿托伐他汀钙片 20 mg/d.治疗前及治疗后第1、2、4、8、12周检测血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)、谷丙转氨酶(ALT)、谷草转氨酶(AST)及肌酸磷酸激酶(CK).结果:治疗12周后,氟伐他汀组的TC、LDL-C和TG分别由治疗前的(6.07±1.23)、(3.33±0.61)、(1.71±0.34)mmol/L降至(3.79±0.41)、(2.46±0.23)、(1.19±0.10) mmol/L,阿托伐他汀组的TC、LDL-C和TG分别由治疗前的(6.03±1.19)、(3.39±0.65)、(1.75±0.37) mmol/L降至(3.87±0.45)、(2.55±0.27)、(1.23±0.13) mmol/L,两组的TC、LDL-C和TG均显著降低(均P＜0.01);氟伐他汀组的不良反应低于阿托伐他汀组,差异有统计学意义(P＜0.05).结论:氟伐他汀钠缓释片与阿托伐他汀钙片的调脂疗效均显著,氟伐他汀钠缓释片的安全性优于阿托伐他汀钙片,氟伐他汀钠缓释片为调脂治疗提供了一种有效、安全、方便的手段.